SCHEMBL3768356

SCHEMBL3768356

CC(C)c1cccc(-c2cnc(N3CCN(CC(=O)N4CCN(C5CCC5)CC4)CC3)cn2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PANK3 Q9H999 2/20 0.42
NPSR1 Q6W5P4 2/20 0.39
HTT P42858 1/20 0.39
PARP1 P09874 1/20 0.38
TP53 P04637 1/20 0.38
HRH3 Q9Y5N1 7/20 0.38
PKM P14618 1/20 0.37
GRM5 P41594 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GRIN2B Q13224 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
DCK P27707 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761039 0.90 PANK3 (0.48) PANK3HRH3
SCHEMBL3774082 0.89 GRM5 (0.47) NPSR1HTTGRM5GRIN2BCYP2C19
SCHEMBL3779446 0.88 KDM4E (0.41) NPSR1HTTTP53HRH3KDM4E
SCHEMBL3776330 0.88 GRIN2B (0.43) NPSR1HTTHRH3GRIN2BKDM4E
SCHEMBL3766131 0.88 HRH3 (0.46) NPSR1HTTPARP1HRH3GRM5
SCHEMBL3773590 0.87 NPC1 (0.41) PANK3NPSR1HTTPARP1TP53
SCHEMBL3769786 0.87 HTT (0.40) NPSR1HTTPARP1HRH3GRM5
SCHEMBL3767426 0.87 KMT2A (0.48) NPSR1HRH3GRM5MEN1KMT2A
SCHEMBL3763022 0.86 ALDH1A1 (0.46) NPSR1HTTPARP1HRH3KDM4E
SCHEMBL3776087 0.86 HRH3 (0.47) HTTTP53HRH3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 PANK3 548/4885NPSR1 357/4885HTT 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.